NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Stage III NSCLC RWE in Chinese Patients

CompletedN/A

Sponsor: AstraZeneca

Conditions: Carcinoma, Non-Small-Cell Lung

Countries: China

The objectives of this study are to assess molecular testing, treatment patterns and associated clinical outcomes in Chinese patients with treatment-naïve stage III non-small cell lung cancer (NSCLC) in real world setting. This study is a prospective, non-interventional study. It is descriptive in nature and does not attempt to test any specific a priori hypotheses.

Eligibility overview

Sex: ALL

Age: 18 Years to 130 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Male or female aged 18 years or older.
* Provision of informed consent prior to any study specific procedures.
* Histologically or cytologically confirmed locally advanced, stage III NSCLC (according to version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology; IASLC Staging Manual in Thoracic Oncology).

Exclusion Criteria:

* Enrolment in studies that prohibit any participation in this observational study.

  * Patients may be concurrently enrolled in unblinded clinical trials, but not blinded clinical trials in which the treatment being administered is unknown.
* Prior surgery, radiotherapy or systemic therapy for NSCLC, including chemotherapy, targeted therapy, anti-angiogenesis, etc.

Locations (25)

Beijing, China, China
Beijing, China, China
Beijing, China, China
Datong, China, China
Datong, China, China
Fenyang, China, China
Guangzhou, China, China
Hefei, China, China
Jinan, China, China
Nanning, China, China
Qingdao, China, China
Shantou, China, China
Taizhou, China, China
Tianjin, China, China
Yinchuan, China, China
Changchun, China
Chengdu, China
Chengdu, China
Hong Kong, China
Shanghai, China
Shanghai, China
Shanghai, China
Shijiazhuang, China
Shijiazhuang, China
Shijiazhuang, China